- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
MannKind Corp (MNKD)
Assess today's live MannKind Corp (MNKD) share price, performance and insights using our live NASDAQ: MNKD stock exchange data.
Analyse the historical data and MannKind Corp share price performance charts on this page. Our technical summary section provides analysis on MannKind share price buy/sell indicators using real-time data (or discuss the MannKind (MNKD) stock price today with other investors in the MannKind NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ MNKD share price (ISIN: US56400P7069) to enhance your trading decisions with our free investment tools and resources.
What Is the MannKind Corp Share Price Today?
The MannKind share price today is 5.660.
What Is the Stock Symbol for MannKind Corp
The stock symbol (or 'ticker') for MannKind Corp is "MNKD."
What Stock Exchange Does MannKind Corp Trade On?
MannKind Corp is listed and trades on the NASDAQ stock exchange.
Is MannKind Corp a Good Stock to Buy?
Determining whether MannKind Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and MannKind Corp share price performance charts on this page. Our technical summary section provides analysis on MannKind share price buy/sell indicators using real-time data (or discuss the MannKind (MNKD) stock price today with other investors in the MannKind NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ MNKD share price (ISIN: US56400P7069) to enhance your trading decisions with our free investment tools and resources.
What Is the MannKind Corp Share Price Today?
The MannKind share price today is 5.660.
What Is the Stock Symbol for MannKind Corp
The stock symbol (or 'ticker') for MannKind Corp is "MNKD."
What Stock Exchange Does MannKind Corp Trade On?
MannKind Corp is listed and trades on the NASDAQ stock exchange.
Is MannKind Corp a Good Stock to Buy?
Determining whether MannKind Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.620
5.765
52 wk Range
3.381
6.510
MNKD is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.6205.765
52 wk Range
3.3816.510
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MNKD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
9.611
Upside
+69.81%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
MannKind Company Profile
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company’s pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
MannKind Corp Earnings Call Summary for Q3/2025
- MannKind reported Q3 2025 EPS of $0.07 (250% above forecast) and revenue of $82.13M (exceeding $80.24M estimate), driving an 8.58% pre-market stock surge to $5.95.
- Revenue grew 17% year-over-year, fueled by 23% increases in both Tyvaso DPI royalties ($33M) and Afrezza net revenue ($18.5M).
- The acquisition of SC Pharmaceuticals is strengthening MannKind's position in cardiorenal medicine, with integration progressing as planned.
- Management provided positive guidance, projecting FDA approval for Afrezza pediatric indication by Q2 2026 and Furoscix auto-injector launch in Q3 2026.
- CEO Michael Castagna highlighted the 'record revenue quarter,' while CFO Chris Prentice expressed unprecedented excitement about revenue growth potential.
Last Updated: 05/11/2025, 15:46
Read Full TranscriptCompare MNKD to Peers and Sector
Metrics to compare | MNKD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMNKDPeersSector | |
|---|---|---|---|---|
P/E Ratio | 59.5x | 6.0x | −0.5x | |
PEG Ratio | 2.53 | 0.26 | 0.00 | |
Price/Book | −39.0x | 4.7x | 2.6x | |
Price / LTM Sales | 5.5x | 8.4x | 3.3x | |
Upside (Analyst Target) | 76.7% | 300.1% | 47.0% | |
Fair Value Upside | Unlock | 14.0% | 6.1% | Unlock |
Analyst Ratings
9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 9.611
(+69.81% Upside)
Earnings
Latest Release
Nov 05, 2025
EPS / Forecast
0.07 / 0.02
Revenue / Forecast
82.13M / 80.24M
People Also Watch
FAQ
What Is the MannKind (MNKD) Share Price Today?
The live MannKind share price today is 5.660
What Stock Exchange Does MannKind (MNKD) Trade On?
MannKind is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for MannKind?
The stock symbol (also called a 'ticker') for MannKind is "MNKD."
What Is the Current MannKind Market Cap?
As of today, MannKind market capitalisation is 1.740B.
What Is MannKind's (MNKD) Earnings Per Share (TTM)?
The MannKind EPS is currently 0.10 (Trailing Twelve Months).
When Is the Next MannKind Earnings Date?
MannKind's next earnings report will be released on 03/03/2026.
Is MNKD a Buy or Sell From a Technical Analyst Perspective?
Based on today's MannKind moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has MannKind Stock Split?
MannKind has split 1 times. (See the MNKD stock split history page for full effective split date and price information.)
How Many Employees Does MannKind Have?
MannKind has 405 employees.
What is the current trading status of MannKind (MNKD)?
As of 14 Feb 2026, MannKind (MNKD) is trading at a price of 5.660, with a previous close of 5.630. The stock has fluctuated within a day range of 5.620 to 5.765, while its 52-week range spans from 3.381 to 6.510.
What Is MannKind (MNKD) Price Target According to Analysts?
The average 12-month price target for MannKind is USD9.611, with a high estimate of USD12 and a low estimate of USD7.5. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +69.81% Upside potential.
What Is the MNKD Premarket Price?
MNKD's last pre-market stock price is 5.710. The pre-market share volume is 4,690.000, and the stock has decreased by 0.080, or 1.420%.
What Is the MNKD After Hours Price?
MNKD's last after hours stock price is 5.710, the stock has decreased by 0.050, or 0.880%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.